Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency
- PMID: 10754381
- DOI: 10.1159/000022514
Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency
Abstract
Congenital plasminogen activator inhibitor-1 (PAI-1) deficiency is an extremely rare disorder characterized by a bleeding diathesis that begins in childhood due to hyperfibrinolysis as a result of decreased PAI-1 activity. We now present 4 unrelated pediatric cases of congenital PAI-1 deficiency. All 4 patients had a history of recurrent episodes of subcutaneous bleeding beginning in early childhood. These episodes were characterized by abnormal prolonged bleeding after trauma, tooth extraction, and surgical procedures, as well as by rebleeding following initial hemostasis. The 2 female patients both had symptoms compatible with hypermenorrhea. The family history was positive in 2 of the 4 patients. Hemostatic screening studies in all 4 patients revealed no abnormalities. Testing for factor XIII antigen, von Willebrand factor antigen, ristocetin cofactor activity, alpha(2)-plasmin inhibitor (alpha2PI) activity, and plasminogen activity was normal. The euglobulin lysis times were shortened in all cases as compared with those in normal control subjects. None of the patients had elevated tissue plasminogen activator (tPA) antigen levels, but PAI activity was markedly decreased in all cases. Three of the patients also had reduced levels of PAI-1 antigen. There tended to be a reduction in tPA-PAI-1 complex in all cases. In addition, 2 patients had elevated PIC (plasmin-alpha2PI complex). Tourniquet tests were performed in 2 patients, with no appreciable rise in PAI-1 activity or PAI-1 antigen levels. The administration of tranexamic acid clearly improved hemorrhagic symptoms in these patients. We considered PAI-1 deficiency to be the likely etiology of the congenital bleeding diatheses in these 4 cases.
Copyright 2000 S. Karger AG, Basel
Similar articles
-
Plasminogen activator inhibitor type 1 deficiency.Haemophilia. 2008 Nov;14(6):1255-60. doi: 10.1111/j.1365-2516.2008.01834.x. Haemophilia. 2008. PMID: 19141166 Review.
-
Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients.Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):144-50. doi: 10.2174/1871529x11313020007. Cardiovasc Hematol Disord Drug Targets. 2013. PMID: 23988002 Review.
-
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.Blood Coagul Fibrinolysis. 2007 Oct;18(7):657-60. doi: 10.1097/MBC.0b013e3282dded21. Blood Coagul Fibrinolysis. 2007. PMID: 17890953
-
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23. doi: 10.1161/01.atv.20.8.2019. Arterioscler Thromb Vasc Biol. 2000. PMID: 10938026
-
Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.J Clin Invest. 1989 May;83(5):1747-52. doi: 10.1172/JCI114076. J Clin Invest. 1989. PMID: 2496147 Free PMC article.
Cited by
-
Effects of epinephrine on angiogenesis-related gene expressions in cultured rat cardiomyocytes.J Biomed Res. 2016 Sep;30(5):380-385. doi: 10.7555/JBR.30.20160024. Epub 2016 Apr 30. J Biomed Res. 2016. PMID: 27845301 Free PMC article.
-
Bleeding diathesis in a child with normal screening tests: think about fibrinolysis.Eur J Pediatr. 2005 Sep;164(9):587-8. doi: 10.1007/s00431-005-1683-2. Epub 2005 Jun 7. Eur J Pediatr. 2005. PMID: 15940466 No abstract available.
-
Functional stability of plasminogen activator inhibitor-1.ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15. ScientificWorldJournal. 2014. PMID: 25386620 Free PMC article. Review.
-
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.J Mol Genet Med. 2014 Oct;8(3):125. doi: 10.4172/1747-0862.1000125. J Mol Genet Med. 2014. PMID: 26110015 Free PMC article. No abstract available.
-
Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield.Res Pract Thromb Haemost. 2022 Mar 15;6(2):e12681. doi: 10.1002/rth2.12681. eCollection 2022 Feb. Res Pract Thromb Haemost. 2022. PMID: 35316940 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Molecular Biology Databases
Miscellaneous